Delving into the Latest Updates on AntoXa Corp. with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

酶	1
单克隆抗体	1

排名前五的靶点	数量

SARS-CoV-2 S protein(新冠病毒刺突蛋白)	1

关联

2

项与 AntoXa Corp. 相关的药物

PhD9 Antibody(PlantForm)

靶点-

作用机制-

在研机构

原研机构

在研适应症

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

recombinant angiotensin converting enzyme-2 therapies (AntoXa)

靶点

SARS-CoV-2 S protein

作用机制

SARS-CoV-2 S protein抑制剂

在研机构

AntoXa Corp.

原研机构

AntoXa Corp.

在研适应症

COVID-19 呼吸道感染

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

100 项与 AntoXa Corp. 相关的临床结果

登录后查看更多信息

0 项与 AntoXa Corp. 相关的专利（医药）

登录后查看更多信息

3

项与 AntoXa Corp. 相关的文献（医药）

2024-04-01·American Journal of Physiology-Lung Cellular and Molecular Physiology

Hemopexin reverses activation of lung eIF2α and decreases mitochondrial injury in chlorine-exposed mice

Article

作者: Yu, Zhihong ; Dubey, Shubham ; Stephens, Emily M. ; Cossar, Douglas ; Ahmad, Israr ; Jilling, Tamas ; Matalon, Sadis ; Meyers, Ashley ; Acosta, Edward P. ; Alishlash, Ammar Saadoon ; Kojima, Kyoko ; Mobley, James A. ; Stewart, Donald

Herein, we demonstrate that exposure of mice to chlorine gas causes significant changes in the lung proteome 24 h post-exposure. Systems biology analysis of the proteomic data is consistent with damage to mitochondria and activation of eIF2, the master regulator of transcription and protein translation. Post-exposure injection of hemopexin, which scavenges free heme, attenuated mtDNA injury, eIF2α phosphorylation, decreased lung injury, and increased survival.

Antibody production in planta

作者: Hall, Jc ; Meyers, Aj ; Grohs, Bm

Viruses3区 · 医学

A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs

3区 · 医学

ArticleOA

作者: Park, Jun-Gyu ; Kobie, James J ; Ye, Chengjin ; Meyers, Ashley J ; Piepenbrink, Michael S ; Nogales, Aitor ; Wang, Haifeng ; Martinez-Sobrido, Luis ; Shuen, Michael

Although seasonal influenza vaccines block most predominant influenza types and subtypes, humans still remain vulnerable to waves of seasonal and new potential pandemic influenza viruses for which no immunity may exist because of viral antigenic drift and/or shift. Previously, we described a human monoclonal antibody (hMAb), KPF1, which was produced in human embryonic kidney 293T cells (KPF1-HEK) with broad and potent neutralizing activity against H1N1 influenza A viruses (IAV) in vitro, and prophylactic and therapeutic activities in vivo. In this study, we produced hMAb KPF1 in tobacco plants (KPF1-Antx) and demonstrated how the plant-produced KPF1-Antx hMAb possesses similar biological activity compared with the mammalian-produced KPF1-HEK hMAb. KPF1-Antx hMAb showed broad binding to recombinant HA proteins and H1N1 IAV, including A/California/04/2009 (pH1N1) in vitro, which was comparable to that observed with KPF1-HEK hMAb. Importantly, prophylactic administration of KPF1-Antx hMAb to guinea pigs prevented pH1N1 infection and transmission in both prophylactic and therapeutic experiments, substantiating its clinical potential to prevent and treat H1N1 infections. Collectively, this study demonstrated, for the first time, a plant-produced influenza hMAb with in vitro and in vivo activity against influenza virus. Because of the many advantages of plant-produced hMAbs, such as rapid batch production, low cost, and the absence of mammalian cell products, they represent an alternative strategy for the production of immunotherapeutics for the treatment of influenza viral infections, including emerging seasonal and/or pandemic strains.

100 项与 AntoXa Corp. 相关的药物交易

登录后查看更多信息

100 项与 AntoXa Corp. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月11日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

临床前

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

PhD9 Antibody(PlantForm)	蓖麻毒素中毒更多	临床前
recombinant angiotensin converting enzyme-2 therapies (AntoXa) ( SARS-CoV-2 S protein )	COVID-19 呼吸道感染更多	药物发现